Trial reportCritical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine2020
The cost-effectiveness of adjunctive corticosteroids for patients with septic shock.
Trial report in Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04567433 (Days Alive and Out of Hospital for Patients With Sepsis), which is not on this map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Days Alive and Out of Hospital for Patients With Sepsis
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Health Economic Evaluations in Intensive Care: An Updated Systematic Review.Critical care explorations · 2025Pooled it
- Health-Related Quality of Life of Adult Sepsis Survivors Following Critical Illness: A Systematic Review.Critical care explorations · 2025Pooled it
- Patient-reported outcomes and experience measures in clinical trials of critically ill adults with sepsis: a scoping review.Annals of the American Thoracic Society · 2026Article
- Impact of sex on outcomes in septic shock patients treated with hydrocortisone.Scientific reports · 2025Observational
- Age- and Sex- Driven Transcriptional and Metabolic Diversity in Myeloid-Derived Suppressor Cells After Mouse Sepsis.bioRxiv : the preprint server for biology · 2025Article
- Uptake of health economic evaluations alongside clinical trials in Australia: an observational study.Trials · 2024Observational
- Recent Data about the Use of Corticosteroids in Sepsis-Review of Recent Literature.Biomedicines · 2024Review
- Sex differences in response to adjunctive corticosteroid treatment for patients with septic shock.Intensive care medicine · 2021Article
- Hydrocortisone in septic shock: is it worth it?Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine whether hydrocortisone is a cost-effective treatment for patients with septic shock.
designData linkage-based cost-effectiveness analysis.
settingNew South Wales and Queensland intensive care units. PARTICIPANTS AND
interventionPatients with septic shock randomly assigned to treatment with hydrocortisone or placebo in the Adjunctive Glucocorticoid Therapy in Patients with Septic Shock (ADRENAL) trial.
main outcome measuresHealth-related quality of life at 6 months using the EuroQoL 5-dimension 5-level questionnaire. Data on hospital resource use and costs were obtained by linking the ADRENAL dataset to government administrative health databases. Clinical outcomes included mortality, health-related quality of life, and quality-adjusted life-years gained; economic outcomes included hospital resource use, costs and cost-effectiveness from the health care payer perspective. We also assessed cost-effectiveness by sex. To increase the precision of cost-effectiveness estimates, we conducted unrestricted bootstrapping.
resultsOf 3800 patients in the ADRENAL trial, 1772 (46.6%) were eligible and 1513 (85.4% of those eligible) were included. There was no difference between hydrocortisone or placebo groups in regards to mortality (218/742 [29.4%]
conclusionsAdjunctive hydrocortisone did not significantly affect longer term mortality, health-related quality of life, health care resource use or costs, and is unlikely to be cost-effective.
Indexed as
Identifiers
32900325PMC10692584What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.